Decent, safe work
B (74)
Screens
Advertising
Alcohol
Cannabis
Carbon emissions intensity
Coal
Deforestation - financing
Deforestation - supply chain
Discrimination controversies
Environmental controversies
Factory farming
Fast food
Firearms
For-profit health care
Fossil fuel
Fur
Gambling
Health-related controversies
Human rights controversies
Human trafficking
Interest-based products
Interest-bearing debt
Interest-bearing securities
Iran
Military contracting
Misleading communication
Music
Myanmar
Norges Bank exclusion list
Northern Ireland (Macbride)
North Korea
Nuclear
Oil and gas
Opioid controversies
Oppressive governments
Pork
Pornography
Predatory lending
Prison involvement
Privacy breaches
Pro-life
Single-use plastic
Sudan
Sugar
Syria
Tobacco
Weapons
Impact

Cause AMGN
Peer rank
Decent, safe work

Name Rating
Loading...
Screens
Advertising
Alcohol
Cannabis
Carbon emissions intensity
Coal
Deforestation - financing
Deforestation - supply chain
Discrimination controversies
Environmental controversies
Factory farming
Fast food
Firearms
For-profit health care
Fossil fuel
Fur
Gambling
Health-related controversies
Human rights controversies
Human trafficking
Interest-based products
Interest-bearing debt
Interest-bearing securities
Iran
Military contracting
Misleading communication
Music
Myanmar
Norges Bank exclusion list
Northern Ireland (Macbride)
North Korea
Nuclear
Oil and gas
Opioid controversies
Oppressive governments
Pork
Pornography
Predatory lending
Prison involvement
Privacy breaches
Pro-life
Single-use plastic
Sudan
Sugar
Syria
Tobacco
Weapons
Top metrics
Sample of top metrics driving Amgen's rating for decent, safe work opportunities (B, relative to other companies). Hover or click on a bubble for more info. See details for all metrics in table below
Loading...
All metrics
Metrics used to rate Amgen for decent, safe work opportunities. Click on a metric for more info
Metric Source Data Normalized
Loading...

Data status

Summary statistics on data used to rate Amgen for decent, safe work opportunities

...

of potential metrics used

...

unique data

...

peer-average data

2 days ago

last updated

...

company filings data

...

government data

...

Ethos research

...

independent organization data
Controversies
Controversies associated with Amgen. Click on a controversy for more info
Title Date Severity
Loading...
* Indicates data is an average of peer group, or industry if peer data not available. Used when data for company not available.
Normalized scores are relative to other companies. Learn more about our ratings methodology
Note that all controversies information is based on publicly-available information.
AMGN Price
$283.74
Last available end-of-day price. Full disclosure
Revenue
$26.33 billion
Market cap
$143.92 billion
Public/private
Public
Hypothetical historical growth of $10,000
Historical performance
Company
Founded
1980
Employees
24,200
Sector
Healthcare
Industry
Pharmaceuticals & Biotech
Peer group
Biotechnology
Headquarters
California, United States
Share classes
AMGN
Mission
To serve patients. And every step of the way, we are guided by the values that define us.
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Material causes
Ethos considers the following causes material for Amgen, based on its industry peer group Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.